7.28 USD
+0.07 (+0.97%)
7.24 USD
-0.04 (-0.55%)
ChartMill assigns a Buy % Consensus number of 85% to XERS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.73. This target is 61.13% above the current price.
XERS was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about XERS.
In the previous month the buy percentage consensus was at a similar level.
XERS was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-10-29 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-07 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-28 | Oppenheimer | Initiate | Outperform |
| 2024-03-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-28 | Craig-Hallum | Initiate | Buy |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-27 | SVB Leerink | Maintains | Outperform |
| 2022-04-28 | Craig-Hallum | Initiate | Buy |
| 2022-02-16 | SVB Leerink | Maintains | Outperform |
| 2021-12-31 | SVB Leerink | Maintains | Outperform |
| 2021-12-31 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-17 | SVB Leerink | Initiate | Outperform |
| 2021-10-29 | HC Wainwright & Co. | Initiate | Buy |
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
What do analysts expect the price target to be for XERIS BIOPHARMA HOLDINGS INC (XERS)?
12 analysts have analysed XERS and the average price target is 11.73 USD. This implies a price increase of 61.13% is expected in the next year compared to the current price of 7.28.
What is the consensus rating for XERS stock?
The consensus rating for XERIS BIOPHARMA HOLDINGS INC (XERS) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.